The COVID 19 vaccines roll out. Controversy erupts. Are aborted fetuses being used in the developing, or testing or manufacture of these drugs? Some say yes, others no. Is this cooperation with intrinsic evil? Again, some say yes, some no. The Leadership of our beloved Church equivocates. The result: much confusion, equivocation, uncertainty. How are we, as faithful Laity, to respond?
Which vaccines of those currently approved and being distributed make use of aborted fetuses, and how? What currently are the alternatives? Are conscience compliant vaccines available? If not why not? And what can we do about it?
On Friday, 9 April 2021, come hear Dr. Alan B. Moy, founder and director of the John Paul II Medical Research Institute, spoke to all of these issues and much more.
Alan B. Moy, MD
Dr. Moy graduated from Creighton University School of medicine in 1985. After completion of Internal Medicine Residency at St. Louis University he proceeded with a Fellowship in Pulmonary and Critical Care at the University of Iowa. He then joined the faculty in the Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa until 2005.
Dr Moy is the President and Scientific Director of the John Paul II Medical Research Institute. He is also the Founder and current President of Cellular Engineering Technologies, Inc.
The John Paul II Medical Research Institute (JP2MRI) focuses on the most ethical and cost-effective way of conducting medical research to help develop therapies and cures for a variety of diseases. Most diseases share a common technical requirement to create therapies. The Institute’s research focuses on these common technical requirements by recruiting patients to procure tissue to develop stem cells and cancer cells for medical research.
The Institute differentiates itself from other research organizations because:
- The Institute does NOT support embryonic stem cell research. It supports only research that is pro-life driven.
- The Institute also devote more than half of its budget towards medical research, a far greater proportion than most established foundations.
Dr. Moy also is currently the president of Pulmonary Associates of Iowa City, PC, which is affiliated with Mercy hospital of Iowa City.
Dr. Moy’s research expertise is in the area of development and application of cellular and tissue engineering technologies, translational cancer biology, biodefense countermeasure systems, preclinical and clinical applications of adult stem cells, industrial somatic stem cell manufacturing, industrial induced pluripotent stem cell reprogramming and cancer stem cell technology.